SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug

The troubles appear to be continuing for beleaguered Regulus Therapeutics (RGLS). Shares of Regulus are down more than 23 percent this morning after pharma giant AstraZeneca (AZN) terminated its involvement with the company’s clinical development program for the treatment of non-alcoholic steatohepatitis (NASH).

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More